INVA Quote, Financials, Valuation and Earnings

Keros Therapeutics, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -51.05%. Innoviva, Inc.'s return on equity of 17.06% beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 62.58%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.38 which suggests that it could grow by 15.38%. Given that Innoviva, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Innoviva, Inc. is more attractive than Keros Therapeutics, Inc..

Innoviva, Inc. has a beta of 0.471, which suggesting that the stock is 52.903% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.815%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. Innoviva, Inc.'s net income of $89.9M is higher than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.34x while Keros Therapeutics, Inc.'s PE ratio is 13.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.93x versus 3.34x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 31.72%. Innoviva, Inc.'s return on equity of 17.06% beat Eli Lilly & Co.'s return on equity of 106.26%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 62.58%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.03%. Given that Innoviva, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Innoviva, Inc. is more attractive than Eli Lilly & Co..

Innoviva, Inc. has a beta of 0.471, which suggesting that the stock is 52.903% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innoviva, Inc. quarterly revenues are $111.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Innoviva, Inc.'s net income of $89.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.34x while Eli Lilly & Co.'s PE ratio is 52.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.93x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 33.68%. Innoviva, Inc.'s return on equity of 17.06% beat Merck & Co., Inc.'s return on equity of 39.63%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 62.58%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 8.85%. Given that Innoviva, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Innoviva, Inc. is more attractive than Merck & Co., Inc..

Innoviva, Inc. has a beta of 0.471, which suggesting that the stock is 52.903% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.85 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innoviva, Inc. quarterly revenues are $111.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Innoviva, Inc.'s net income of $89.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.34x while Merck & Co., Inc.'s PE ratio is 13.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.93x versus 3.99x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 21.32%. Innoviva, Inc.'s return on equity of 17.06% beat Pfizer Inc.'s return on equity of 10.84%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 62.58%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 13.63%. Given that Innoviva, Inc. has higher upside potential than Pfizer Inc., analysts believe Innoviva, Inc. is more attractive than Pfizer Inc..

Innoviva, Inc. has a beta of 0.471, which suggesting that the stock is 52.903% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.83% to investors and pays a quarterly dividend of $0.43 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Innoviva, Inc.'s net income of $89.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.34x while Pfizer Inc.'s PE ratio is 14.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.93x versus 2.29x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.